Prime Medicine

About

Prime Medicine operates as a biotechnology company that delivers the promise of gene editing using Prime Editing.

Cambridge,Massachusetts,United States
101 - 250
https://www.primemedicine.com

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: $115M
Industries: Biotechnology,Genetics,Life Science,Medical
Founded date: Jan 1, 2019
Number Of Employee: 101 - 250
Operating Status: Active
Stock Symbol: nasdaq:PRME
Legal Name: Prime Medicine, Inc.

Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease.

It was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

$490M

Prime Medicine has raised a total of $490M in funding over 2 rounds. Their latest funding was raised on Oct 20, 2022 from a IPO round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Oct 20, 2022	IPO	$175M	—	—	—	Detail
Jul 13, 2021	Series B	$200M	12	—	—	Detail
Oct 22, 2019	Series A	$115M	5	ARCH Venture Partners F-Prime Capital GV	—	Detail

Investors

Number of Lead Investors

Number of Investors

3

12

Prime Medicine is funded by 12 investors. ARCH Venture Partners and Arrive are the most recent investors.

Investor Name	Lead Investor	Funding Round
ARCH Venture Partners	—	Series B
Arrive	—	Series B
Casdin Capital	—	Series B
Cormorant Asset Management	—	Series B
F-Prime Capital	—	Series B
GV	—	Series B
Moore Strategic Ventures	—	Series B
Newpath Management	—	Series B
PSP Investments	—	Series B
Redmile Group	—	Series B